Biotech - Spark Newswire

2 minute read

Cerecor Licenses Immune Checkpoint Program From Sanford Burnham Prebys Further Expanding Pipeline Of Immunology And Immuno-oncology Targets

Today, 2:42 PM

Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunology, immuno-oncology and rare genetic disorders, today announced that

CERC

2 minute read

Cytokinetics Announces Three Presentations To Occur At European Society Of Cardiology Heart Failure 2021 Congress Jun. 29

By Bill Haddad

Today, 2:42 PM

SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced three presentations at Heart Failure 2021, an International Congress of the European Society of

CYTK

2 minute read

Bausch + Lomb Expands Parameters For Bausch + Lomb ULTRA Multifocal For Astigmatism Contact Lenses

By Bill Haddad

Today, 2:42 PM

New Parameters Provide a Broader Offering for Presbyopic Patients with Astigmatism LAVAL, QB, June 23, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies

BHC

3 minute read

VBI Vaccines And Brii Biosciences Highlight Presentation Of Positive Data From Completed Phase 1b/2a Study On BRII-179 (VBI-2601) In Patients With Chronic Hepatitis B At International Liver Congress 2021

By Bill Haddad

Today, 2:42 PM

Data demonstrate that BRII-179 (VBI-2601) induced both B cell (antibody) and T cell responses in chronically-infected hepatitis B (HBV) patients, and was well-tolerated with no safety signals observed Results support

VBIV

4 minute read

Gamida Cell Highlights Publication In Blood, The Journal Of The American Society Of Hematology, Of First Pivotal Trial To Evaluate a Cell Therapy (Omidubicel) For Patients With Blood Cancer Who Require Allogeneic Stem Cell Transplant

By Bill Haddad

Today, 2:42 PM

Omidubicel is a first-in-class, NAM-enabled, advanced cell therapy being evaluated as a potential life-saving treatment for patients with blood cancers in need of an allogeneic hematopoietic stem cell (bone marrow)

GMDA

3 minute read

Karuna Therapeutics Announces Results From Phase 1b Trial Evaluating Safety And Tolerability Of KarXT In Healthy Elderly Volunteers; Co. To Initiate Phase 2 Trial In 2H 2022

By Bill Haddad

Today, 2:42 PM

Company to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in the first half of 2022 Results suggest that KarXT can be administered to elderly volunteers at doses which achieve xanomeline blood

KRTX

1 minute read

United Therapeutics And Medtronic Discontinue Further Efforts To Develop & Commercialize Implantable System For Remodulin Based On Evolution Of Treatment Options, Paradigms In Pulmonary Arterial Hypertension Over Past Few Years

By Bill Haddad

Today, 2:42 PM

On June 22, 2021, United Therapeutics Corporation (the “Company”) and Medtronic, Inc. (“Medtronic”) agreed to discontinue further efforts to develop and commercialize the Implantable

MDT

2 minute read

Sorrento Therapeutics Is Forming Pennant Pattern: Technical Levels To Watch

By Tyler Bundy

Today, 2:42 PM

Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares moved higher Tuesday after the company announced Phase 2 Abivertinib clinical studies have completed patient enrollment in the U.S. and Brazil. The company is expecting top-line clinical data at the end of the third quarter.

SRNE

3 minute read

Keros Therapeutics Earlier Announced Preliminary Results From Phase 2 Clinical Trial Evaluating KER-050; Says Five Patients That Completed Eight Weeks Of Treatment Met At Least One Endpoint

By Bill Haddad

Today, 2:42 PM

LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of

KROS

5 minute read

Gemini Therapeutics Shares Down 38.6%; Co. Earlier Announced Initial Data From Ongoing Phase 2a Study Of GEM103 In Patients With Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration

By Bill Haddad

Today, 2:42 PM

– Biomarker results indicate GEM103's ability to regulate complement and complement factor H therapeutic approach in geographic atrophy – – GEM103 continues to be well-tolerated and

GMTX